TY - JOUR
T1 - Elevated polygenic burden for autism is associated with differential DNA methylation at birth
AU - iPSYCH-Broad ASD Group
AU - Hannon, Eilis
AU - Schendel, Diana
AU - Ladd-Acosta, Christine
AU - Grove, Jakob
AU - Hansen, Christine Søholm
AU - Andrews, Shan V.
AU - Hougaard, David Michael
AU - Bresnahan, Michaeline
AU - Mors, Ole
AU - Hollegaard, Mads Vilhelm
AU - Bækvad-Hansen, Marie
AU - Hornig, Mady
AU - Mortensen, Preben Bo
AU - Børglum, Anders D.
AU - Werge, Thomas
AU - Pedersen, Marianne Giørtz
AU - Nordentoft, Merete
AU - Buxbaum, Joseph
AU - Daniele Fallin, M.
AU - Bybjerg-Grauholm, Jonas
AU - Reichenberg, Abraham
AU - Mill, Jonathan
AU - Agerbo, Esben
AU - Als, Thomas D.
AU - Belliveau, Rich
AU - Bækved-Hansen, Marie
AU - Børglum, Anders
AU - Cerrato, Felecia
AU - Christensen, Jane
AU - Chambert, Kimberly
AU - Churchhouse, Claire
AU - Daly, Mark
AU - Demontis, Ditte
AU - Dumont, Ashley
AU - Goldstein, Jacqueline
AU - Hansen, Christine
AU - Hauberg, Mads
AU - Hougaard, David
AU - Howrigan, Daniel
AU - Huang, Hailiang
AU - Maller, Julian
AU - Martin, Alicia
AU - Martin, Joanna
AU - Mattheisen, Manuel
AU - Moran, Jennifer
AU - Neale, Benjamin
AU - Nyegaard, Mette
AU - Pallsen, Jonatan
AU - Palmer, Duncan
AU - Pedersen, Carsten
N1 - Funding Information:
This study was supported by grant HD073978 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, and National Institute of Neurological Disorders and Stroke; and by the Beatrice and Samuel A. Seaver Foundation. We acknowledge iPSYCH and The Lundbeck Foundation for providing samples and funding. The iPSYCH (The Lundbeck Foundation Initiative for Integrative Psychiatric Research) team acknowledges funding from The Lundbeck Foundation (grant numbers R102-A9118 and R155-2014-1724), the Stanley Medical Research Institute, the European Research Council (project number 294838), the Novo Nordisk Foundation for supporting the Danish National Biobank resource, and grants from Aarhus and Copenhagen Universities and University Hospitals, including support to the iSEQ Center, the GenomeDK HPC facility, and the CIRRAU Center. This research has been conducted using the Danish National Biobank resource, supported by the Novo Nordisk Foundation. JM is supported by funding from the UK Medical Research Council (MR/K013807/1) and a Distinguished Investigator Award from the Brain & Behavior Research Foundation. The SEED study was supported by Centers for Disease Control and Prevention (CDC) Cooperative Agreements announced under the RFAs 01086, 02199, DD11-002, DD06-003, DD04-001, and DD09-002 and the SEED DNA methylation measurements were supported by Autism Speaks Award #7659 to MDF. SA was supported by the Burroughs-Wellcome Trust training grant: Maryland, Genetics, Epidemiology and Medicine (MD-GEM). The SSC was supported by Simons Foundation (SFARI) award and NIH grant MH089606, both awarded to STW.
Funding Information:
This study was supported by grant HD073978 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, and National Institute of Neurological Disorders and Stroke; and by the Beatrice and Samuel A. Seaver Foundation. We acknowledge iPSYCH and The Lundbeck Foundation for providing samples and funding. The iPSYCH (The Lundbeck Foundation Initiative for Integrative Psychiatric Research) team acknowledges funding from The Lundbeck Foundation (grant numbers R102-A9118 and R155–2014-1724), the Stanley Medical Research Institute, the European Research Council (project number 294838), the Novo Nordisk Foundation for supporting the Danish National Biobank resource, and grants from Aarhus and Copenhagen Universities and University Hospitals, including support to the iSEQ Center, the GenomeDK HPC facility, and the CIRRAU Center. This research has been conducted using the Danish National Biobank resource, supported by the Novo Nordisk Foundation. JM is supported by funding from the UK Medical Research Council (MR/ K013807/1) and a Distinguished Investigator Award from the Brain & Behavior Research Foundation. The SEED study was supported by Centers for Disease Control and Prevention (CDC) Cooperative Agreements announced under the RFAs 01086, 02199, DD11–002, DD06–003, DD04–001, and DD09–002 and the SEED DNA methylation measurements were supported by Autism Speaks Award #7659 to MDF. SA was supported by the Burroughs-Wellcome Trust training grant: Maryland, Genetics, Epidemiology and Medicine (MD-GEM). The SSC was supported by Simons Foundation (SFARI) award and NIH grant MH089606, both awarded to STW.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/3/28
Y1 - 2018/3/28
N2 - Background: Autism spectrum disorder (ASD) is a severe neurodevelopmental disorder characterized by deficits in social communication and restricted, repetitive behaviors, interests, or activities. The etiology of ASD involves both inherited and environmental risk factors, with epigenetic processes hypothesized as one mechanism by which both genetic and non-genetic variation influence gene regulation and pathogenesis. The aim of this study was to identify DNA methylation biomarkers of ASD detectable at birth. Methods: We quantified neonatal methylomic variation in 1263 infants-of whom ~ 50% went on to subsequently develop ASD-using DNA isolated from archived blood spots taken shortly after birth. We used matched genotype data from the same individuals to examine the molecular consequences of ASD-associated genetic risk variants, identifying methylomic variation associated with elevated polygenic burden for ASD. In addition, we performed DNA methylation quantitative trait loci (mQTL) mapping to prioritize target genes from ASD GWAS findings. Results: We identified robust epigenetic signatures of gestational age and prenatal tobacco exposure, confirming the utility of DNA methylation data generated from neonatal blood spots. Although we did not identify specific loci showing robust differences in neonatal DNA methylation associated with later ASD, there was a significant association between increased polygenic burden for autism and methylomic variation at specific loci. Each unit of elevated ASD polygenic risk score was associated with a mean increase in DNA methylation of - 0.14% at two CpG sites located proximal to a robust GWAS signal for ASD on chromosome 8. Conclusions: This study is the largest analysis of DNA methylation in ASD undertaken and the first to integrate genetic and epigenetic variation at birth. We demonstrate the utility of using a polygenic risk score to identify molecular variation associated with disease, and of using mQTL to refine the functional and regulatory variation associated with ASD risk variants.
AB - Background: Autism spectrum disorder (ASD) is a severe neurodevelopmental disorder characterized by deficits in social communication and restricted, repetitive behaviors, interests, or activities. The etiology of ASD involves both inherited and environmental risk factors, with epigenetic processes hypothesized as one mechanism by which both genetic and non-genetic variation influence gene regulation and pathogenesis. The aim of this study was to identify DNA methylation biomarkers of ASD detectable at birth. Methods: We quantified neonatal methylomic variation in 1263 infants-of whom ~ 50% went on to subsequently develop ASD-using DNA isolated from archived blood spots taken shortly after birth. We used matched genotype data from the same individuals to examine the molecular consequences of ASD-associated genetic risk variants, identifying methylomic variation associated with elevated polygenic burden for ASD. In addition, we performed DNA methylation quantitative trait loci (mQTL) mapping to prioritize target genes from ASD GWAS findings. Results: We identified robust epigenetic signatures of gestational age and prenatal tobacco exposure, confirming the utility of DNA methylation data generated from neonatal blood spots. Although we did not identify specific loci showing robust differences in neonatal DNA methylation associated with later ASD, there was a significant association between increased polygenic burden for autism and methylomic variation at specific loci. Each unit of elevated ASD polygenic risk score was associated with a mean increase in DNA methylation of - 0.14% at two CpG sites located proximal to a robust GWAS signal for ASD on chromosome 8. Conclusions: This study is the largest analysis of DNA methylation in ASD undertaken and the first to integrate genetic and epigenetic variation at birth. We demonstrate the utility of using a polygenic risk score to identify molecular variation associated with disease, and of using mQTL to refine the functional and regulatory variation associated with ASD risk variants.
KW - Autism
KW - Birth
KW - DNA methylation
KW - DNA methylation quantitative trait loci (mQTL)
KW - Epigenome-wide association study (EWAS)
KW - Genetics
KW - Genome-wide association study (GWAS)
KW - Neonatal
KW - Polygenic risk score
KW - Prenatal smoking
UR - http://www.scopus.com/inward/record.url?scp=85044353251&partnerID=8YFLogxK
U2 - 10.1186/s13073-018-0527-4
DO - 10.1186/s13073-018-0527-4
M3 - Article
C2 - 29587883
AN - SCOPUS:85044353251
SN - 1756-994X
VL - 10
JO - Genome Medicine
JF - Genome Medicine
IS - 1
M1 - 19
ER -